Company
EMV Capital
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
424 stories · page 5 of 22
Netscientific says portfolio company PDS to start advanced head and neck cancer study
This latest study involves two groups of patients with HPV16-positive head and neck cancer that has returned or spread
NetScientific climbs as PDS Biotech cancer trial logs 100% response
On day 170 of the trial, eight of the nine had no evidence of disease (a complete response)
NetScientific chairman to step down next year
He has agreed to provide consultancy and advisory services to group companies until the end of next year
NetScientific highlights progress of PDS Biotech cancer treatment
"Taken together, the data being presented demonstrate the potential ability of PDS0101 to elicit in patients the right type and quality of therapeutic immune response."
NetScientific subsidiary takes stake in heat pump system maker
"This is a perfect example of our differentiated business model and pro-active investment strategy in action," said NetScientific chief Ilian Iliev
NetScientific portfolio opportunities are “significantly undervalued”, says broker
On October 11, 2022, PDS Biotechnology - in which Netscientific holds a 4.72% stake - announced expanded interim data from a National Cancer Institute-led Phase II clinical study evaluating its lead candidate PDS0101 in combination with two
NetScientific portfolio company PDS ahead of schedule for key cancer therapy trial
It was earlier this year granted FDA fast-track designation
NetScientific says portfolio well funded at half-year stage
Work was said to be ongoing within several portfolio companies “on substantial liquidity events or routes to exit”
NetScientific portfolio company PDS Biotechnology Corporation completes US$35mln financing agreement
Loan will help achieve important milestones across the company’s oncology and infectious disease programmes
NetScientific completes Vortex stake buy; investee company appoints CEO
Paul Jones has been drafted in to lead Vortex on the next stage of its journey
Netscientific 'pleased' with progress at PDS Biotech
Lead product PDS0101 was granted fast-track designation by the US Food and Drug Administration in combination with Merck’s blockbuster drug KEYTRUDA
NetScientific raises £1.5mln to further growth strategy
The placing shares will represent approximately 9.6% of the company's issued share capital following completion
Netscientific increases stake in Q-Bot
"Q-Bot has been a very good investment for us," said CEO Ilian Iliev
NetScientific's investment in Q-Bot shows ability to drive value, says broker
Based on the revised valuation of Q-Bot, the analyst said the sum-of-the-parts analysis implies fair value of 190p per share
NetScientific ups investment in robot-powered home insulation company
NetScientific's 20.6% direct stake in Q-Bot is now valued at £2.77mln, a gain of about £1.45mln in less than a year
NetScientific shares spike after FDA fast-tracks immunotherapy cancer drug
The FDA’s fast-track designation programme aims to expedite drugs that could treat life-threatening conditions and address unmet needs
NetScientific portfolio company PDS to update progress at ASCO 2022
The second phase of its clinical trials looked at combinations of checkpoint inhibitors and chemotherapy, with up to three different drug combinations